Theravance Biopharma, Inc. Loss Contingency, Number of Defendants
Theravance Biopharma, Inc. (TBPH) reported Loss Contingency, Number of Defendants of 2 item for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyNumberOfDefendants · last filed 2025-08-13
- 2024-12-31: Loss Contingency, Number of Defendants 1 month 3.00 company.
- 2024-10-31: Loss Contingency, Number of Defendants 3.00 company.
- 2024-08-31: Loss Contingency, Number of Defendants 1 month 3.00 company.
- 2024-06-30: Loss Contingency, Number of Defendants 6 month 3.00 company.
company
| Period end | Loss Contingency, Number of Defendants | Loss Contingency, Number of Defendants 1 month | Loss Contingency, Number of Defendants 6 month |
|---|---|---|---|
| 2024-12-31 | 3.00 company 10-K · filed 2025-03-07 | ||
| 2024-10-31 | 3.00 company 10-Q · filed 2024-11-14 | ||
| 2024-08-31 | 3.00 company 10-K · filed 2025-03-07 | ||
| 2024-06-30 | 3.00 company 10-Q · filed 2024-08-08 |
item
| Period end | Loss Contingency, Number of Defendants 1 month | Loss Contingency, Number of Defendants 3 month | Loss Contingency, Number of Defendants 6 month |
|---|---|---|---|
| 2025-06-30 | 2.00 item 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | 3.00 item 10-Q · filed 2025-05-12 | ||
| 2024-08-31 | 3.00 item 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |